nach oben

Diabetologia

Erschienen in:

01.09.2006 | Commentary

Is omega-3 key to unlocking inflammation in obesity?

verfasst von: P. J. White, A. Marette

Erschienen in: Diabetologia | Ausgabe 9/2006

Einloggen, um Zugang zu erhalten

Excerpt

Low-grade inflammation has been identified as a key player in the development of the metabolic syndrome in obese subjects, leading the way to type 2 diabetes and cardiovascular diseases. Insulin resistance, a primary component of the metabolic syndrome, is characterised by chronically elevated concentrations of proinflammatory cytokines, acute phase proteins, and enhanced activation of proinflammatory signalling in insulin-responsive tissues of obese subjects. …

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808PubMed

Xu H, Barnes GT, Yang Q et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830PubMed

Arkan MC, Hevener AL, Greten FR et al (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11:191–198PubMedCrossRef

Weisberg SP, Hunter D, Huber R et al (2006) CCR2 modulates inflammatory and metabolic effects of high fat feeding. J Clin Invest 116:115–124PubMedCrossRef

Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS (1987) Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 237:885–888PubMedCrossRef

Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J (1994) Long term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12 month, double blind, controlled study. Arthritis Rheum 37:824–829PubMedCrossRef

Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M (1996) Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 334:1557–1560PubMedCrossRef

Rallidis LS, Paschos G, Liakos GK, Velissaridou AH, Anastasiadis G, Zampelas A (2003) Dietary α-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis 167:237–242PubMedCrossRef

Trebble T, Arden NK, Stroud MA et al (2003) Inhibition of tumour necrosis factor-α and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr 90:405–412PubMedCrossRef

10.

Todoric J, Löffler M, Huber J et al (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n−3 polyunsaturated fatty acids. Diabetologia DOI 10.1007/s00125-006-0300-x

11.

Lee TH, Mencia-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF (1984) Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest 74:1922–1933PubMedCrossRef

12.

Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H (1979) Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A 76:944–948PubMedCrossRef

13.

Corey EJ, Shih C, Cashman JR (1983) Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A 80:3581–3584PubMedCrossRef

14.

Hughes DA (1998) In vitro and in vivo effects of n−3 polyunsaturated fatty acids on human monocyte function. Proc Nutr Soc 57:521–525PubMedCrossRef

15.

Bannenberg GL, Chiang N, Ariel A et al (2005) Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 174:4345–4355PubMed

16.

Kliewer SA, Sundseth SS, Jones SA et al (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci U S A 94:4318–4323PubMedCrossRef

17.

Neschen S, Morino K, Rossbacher JC et al (2006) Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-γ-dependent mechanism in mice. Diabetes 55:924–928PubMedCrossRef

18.

Pilon G, Dallaire P, Marette A (2004) Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 279:20767–20774PubMedCrossRef

19.

Lee CH, Chawla A, Urbiztondo N et al (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 302:453–457PubMedCrossRef

20.

Tsuchida A, Yamauchi T, Takekawa S et al (2005) Peroxisome proliferator-activated receptor (PPAR) α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARγ, and their combination. Diabetes 54:3358–3370PubMedCrossRef

21.

Xu HE, Lambert MH, Montana VG et al (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397–403PubMedCrossRef

22.

Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator activated receptor-γ is a negative regulator of macrophage activation. Nature 319:79–82CrossRef

23.

Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMedCrossRef

24.

Yamauchi T, Kamon J, Waki H et al (2001) The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMedCrossRef

25.

Carmona MC, Louch K, Nibbelink M et al. (2005) Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes 29:864–871CrossRef

26.

Wang H, Storlien LH, Huang XF (2002) Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am J Physiol Endocrinol Metab 282:E1352–E1359PubMed

Titel: Is omega-3 key to unlocking inflammation in obesity?
verfasst von: P. J. White
A. Marette
Publikationsdatum: 01.09.2006
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 9/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0346-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Is omega-3 key to unlocking inflammation in obesity?

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2006

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione

The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study

Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer’s disease and decreases it in wild-type mice

Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA

Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients

Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin